Company intelligence / Profile preview

Kinstate

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Kinnate’s lead asset exarafenib (KIN-2787), a selective pan-RAF inhibitor, is in Phase 1/1b trials for advanced solid tumors driven by BRAF/NRAS alterations; early clinical data focus on safety, tolerability, and pharmacodynamics. KIN-3248 targets FGFR2/3, also in early-stage development. Additional preclinical assets include MEK and c-MET inhibitors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Precision medicine cancer centersresearch institutions

Beyond the preview

Go deeper on Kinstate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinstate.

Explore the full profile